A New Vaccine for Advanced Pancreatic Cancer
An mRNA vaccine that works against KRAS mutations is being tested with and without immunotherapy for advanced or metastatic pancreatic cancer.
Safety and Effectiveness of a New Drug for Advanced Pancreatic Cancer
Researchers are testing dose safety and effectiveness of a new drug for pancreatic cancer, in combination with gemcitabine.
Testing the Safety of an Immunotherapy Combination After Surgery
A new clinical trial tests the safety of a monoclonal antibody and personalized cancer vaccine combined with chemotherapy after surgery to remove pancreatic cancer.
Drug Combination to Combat Pancreatic and other Gastrointestinal Cancers
Researchers are combining TAS-102, an approved drug for colorectal cancer, and nanoliposomal irinotecan, to see if they work on pancreatic and other gastrointestinal cancers.
CAR T Cell Trial Targets Mesothelin
In an immunotherapy clinical trial, Dr. Mark O'Hara is using CAR T cells to attack mesothelin-expressing tumor cells in pancreatic cancer.
Immunotherapy to Attack a Common Pancreatic Cancer Mutation
Researchers are testing a type of immunotherapy to attack a variant of the KRAS mutation; KRAS mutations occur in almost all pancreatic cancers.
Combination Delivers a Dual Punch to Pancreatic Cell Growth
Dr. Conan Kinsey outlines a clinical trial that has moved quickly from the lab to phase I, with a dual approach to delivering pancreatic cancer treatment.
Targeting Cancer-Associated Wasting With Experimental Immunotherapy
Wasting, or cachexia, is the focus of a clinical trial testing a cachexia immunotherapy treatment combined with standard pancreatic cancer treatment.
Personalized Immunotherapy Vaccine for Pancreatic Cancer
Researchers are creating personalized vaccines to stimulate a pancreatic cancer patient's immune system after surgery and chemotherapy.
Targeting Tumor Proteins Specific to Pancreatic Cancer Cells
A clinical trial tests the safety and effectiveness of tumor-associated antigen-specific cytotoxic T lymphocytes, which target specific tumor proteins.